

Drugs and Therapeutics Advisory Board Meeting

Thursday, January 13, 2022 8:30am-11am

Agenda

- I. Call to Order
- II. Roll Call
- III. Welcome
- IV. Agenda and Conflict of Interest Review
- V. Approval of the Minutes
- VI. Public Comments
- VII. PDL Drug Appeals
 - a. None at this meeting
- VIII. New Drug Appeals (with discussion and vote)
 - a. Qelbree (Viloxazine HCL Cap ER)-Michael Feld, MD
- IX. Drug Class Review- Ryan Rodriguez, PharmD Clinical review (with discussion and vote)
 - a. Antiasthmatics-Adrenergic
 - b. Antiasthmatics-Anticholinergic
- X. New Drug Initial Review-Ryan Rodriguez, PharmD (with discussion and vote)
 - a. Lybalvi (Olanzapine-Samidorphane L-malate)
 - b. Invega Hafyera (Paliperidone Palmitate)
 - c. Myfembree (Regugolix-Estradiol-Norethindrone Acetate)
 - d. Qulipta (Atogepant)
- XI. Future Agenda Preview -Sheri Dolan
- XII. Provider Requested Reviews-Sheri Dolan
 - a. None at this meeting
- XIII. Department Update-Jose Jimenez

The department is seeking doctors from central and southern Illinois to serve on our Drug Utilization Review board. If you know a physician you think fits the bill please send contact information to Sheri.
- XIV. Adjournment

Call-In Information for this meeting can be found at the top of page:
<https://www2.illinois.gov/hfs/MedicalProviders/Pharmacy/Pages/ClassReviewSchedule.aspx>

Scheduled Speakers

Speaker	Product	Organization
Cassandra Lickert, MD	Myfembree	Myovant Sciences, Inc.
Rudy Christian, DrPH	Lybalvi	Alkermes
Jenish Patel, PharmD.	Invega Hafyera	Janssen
Michael Feld, MD	Qelbree	Michael Feld, MD SC
Christopher Rhyne, MD	Qulipta	Diamond Headache Clinic
**George Vass, PharmD	Qulipta	AbbVie

**George will speak as backup only if Dr. Rhyne cannot be present.